TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Eight Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension
Brief Summary: This study is designed to investigate the efficacy, safety and tolerability of aliskiren 300 mg, 150 mg and 75 mg when compared to ramipril 5 mg in patients with essential hypertension.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MK8141 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MK8141 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Intervention Type: DRUG; Name: MK8141; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): 3
B: Arm Label: Aliskiren 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Aliskiren 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Aliskiren 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Ramipril 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren 150 mg, Aliskiren 300 mg, Aliskiren 75 mg | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril 5 mg
C: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Other: Placebo to Ramipril | Arm Label: Ramipril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Other: Placebo to Aliskiren | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril | Intervention Type: OTHER; Name: Placebo to Ramipril; Assigned to Arm(s): Aliskiren | Intervention Type: OTHER; Name: Placebo to Aliskiren; Assigned to Arm(s): Ramipril
D: Arm Label: Ramipril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Drug: Matching placebo to Aliskiren | Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Matching placebo to Ramipril | Arm Label: Placebo to Ramipril; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo to Ramipril | Arm Label: Placebo to Aliskiren; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo to Aliskiren | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril | Intervention Type: DRUG; Name: Matching placebo to Aliskiren; Assigned to Arm(s): Placebo to Aliskiren, Ramipril | Intervention Type: DRUG; Name: Matching placebo to Ramipril; Assigned to Arm(s): Aliskiren, Placebo to Ramipril

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Six-week Double Blinded, Randomized Trial of Atorvastatin for the Treatment of PCOS Women With Elevated LDL Cholesterol
Brief Summary: The purpose of this study is to determine the efficacy of Lipitor (Atorvastatin) for the treatment of PCOS with elevated LDL cholesterol.


Options:
A: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo
B: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin and Metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): N/A
D: Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Lipitor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lipitor; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Six-week Double Blinded, Randomized Trial of Atorvastatin for the Treatment of PCOS Women With Elevated LDL Cholesterol
Brief Summary: The purpose of this study is to determine the efficacy of Lipitor (Atorvastatin) for the treatment of PCOS with elevated LDL cholesterol.


Options:
A: Arm Label: atovastatin; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): atovastatin
B: Arm Label: active treatment; Type: EXPERIMENTAL; Interventions: Drug: atorvastatin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): active treatment | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Lipitor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lipitor; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal
Brief Summary: The purpose of this trial is to compare the acceptability, efficacy and safety of three alternative drug regimens for use for seasonal Intermittent Preventive Treatment to prevent malaria in children. Children aged 2 months to 5 years will be randomized to receive IPT with one of three regimens during the transmission season: sulfadoxine-pyrimethamine (SP) plus amodiaquine, show to be highly effective for IPT in a recent trial; SP plus piperaquine, used for malaria prophylaxis in China for many years; or Duocotexcin (a combination of piperaquine with an artemisinin).


Options:
A: Arm Label: Combination of Amodiaquine +sulfadoxine-pyrimethamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: amodiaquine + sulfadoxine-pyrimethamine | Arm Label: Dihydroartemisinin-piperaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Sulfadoxine-pyrimethamine alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): Sulfadoxine-pyrimethamine alone | Intervention Type: DRUG; Name: amodiaquine + sulfadoxine-pyrimethamine; Assigned to Arm(s): Combination of Amodiaquine +sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine; Assigned to Arm(s): Dihydroartemisinin-piperaquine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: SP and amodiaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP plus amodiaquine | Arm Label: SP placebo plus amodiaquine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: SP placebo plus amodiaquine placebo | Intervention Type: DRUG; Name: SP plus amodiaquine; Assigned to Arm(s): SP and amodiaquine | Intervention Type: DRUG; Name: SP placebo plus amodiaquine placebo; Assigned to Arm(s): SP placebo plus amodiaquine placebo
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment with AQ+ SP | Intervention Type: DRUG; Name: Intermittent preventive treatment with AQ+ SP; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfalene-pyrimethamine plus amodiaquine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin plus piperaquine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine pyrimethamine plus piperaquine | Intervention Type: DRUG; Name: sulfalene-pyrimethamine plus amodiaquine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dihydroartemisinin plus piperaquine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: sulfadoxine pyrimethamine plus piperaquine; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal
Brief Summary: The purpose of this trial is to compare the acceptability, efficacy and safety of three alternative drug regimens for use for seasonal Intermittent Preventive Treatment to prevent malaria in children. Children aged 2 months to 5 years will be randomized to receive IPT with one of three regimens during the transmission season: sulfadoxine-pyrimethamine (SP) plus amodiaquine, show to be highly effective for IPT in a recent trial; SP plus piperaquine, used for malaria prophylaxis in China for many years; or Duocotexcin (a combination of piperaquine with an artemisinin).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfalene-pyrimethamine plus amodiaquine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin plus piperaquine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine pyrimethamine plus piperaquine | Intervention Type: DRUG; Name: sulfalene-pyrimethamine plus amodiaquine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dihydroartemisinin plus piperaquine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: sulfadoxine pyrimethamine plus piperaquine; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: artesunate-amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment (SP and amodiaquine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Intermittent preventive treatment (SP and amodiaquine); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Open-Label Trial of the Efficacy of Artemether-Lumefantrine Suspension Compared With Artemether-Lumefantrine Tablets for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Less Than Five Years in Western Kenya
Brief Summary: The purpose of this study is to compare the safety and efficacy in children aged 6 - 59 months with uncomplicated malaria, treated with either conventional artemether/lumefantrine tablets(Coartem®) or artemether/ lumefantrine suspension (Co-artesiane®) in Western Kenya


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether/lumefantrine tablets | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether/Lumefantrine suspension | Intervention Type: DRUG; Name: Artemether/lumefantrine tablets; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Artemether/Lumefantrine suspension; Assigned to Arm(s): B
B: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
C: Arm Label: Eurartesim dispersible oral tablets; Type: EXPERIMENTAL; Interventions: Drug: Eurartesim dispersible oral tablet | Arm Label: Eurartesim film coated tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: eurartesim film coated tablet | Intervention Type: DRUG; Name: Eurartesim dispersible oral tablet; Assigned to Arm(s): Eurartesim dispersible oral tablets | Intervention Type: DRUG; Name: eurartesim film coated tablet; Assigned to Arm(s): Eurartesim film coated tablet
D: Arm Label: co-formulated Amodiaquine-Artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: amodiaquine-artesunate (AQAS) fixed-dose | Arm Label: artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination (AL) dispersable | Intervention Type: DRUG; Name: amodiaquine-artesunate (AQAS) fixed-dose; Assigned to Arm(s): co-formulated Amodiaquine-Artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination (AL) dispersable; Assigned to Arm(s): artemether-lumefantrine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The purpose of this study was to establish the efficacy and safety of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous (SC) interferon beta-1a (Rebif®). The study had enrolled participants who had not previously received MS disease-modifying therapies. Participants had monthly laboratory tests and comprehensive testing every 3 months.


Options:
A: Intervention Type: DRUG; Name: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody); Assigned to Arm(s): N/A
B: Arm Label: Alemtuzumab; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab; Assigned to Arm(s): Alemtuzumab | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a
C: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Interferon β-1a 30 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a 30 µg | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Interferon β-1a 30 µg; Assigned to Arm(s): Interferon β-1a 30 µg
D: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The purpose of this study was to establish the efficacy and safety of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous (SC) interferon beta-1a (Rebif®). The study had enrolled participants who had not previously received MS disease-modifying therapies. Participants had monthly laboratory tests and comprehensive testing every 3 months.


Options:
A: Arm Label: Atacicept 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to atacicept | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 25 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 75 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 150 mg | Intervention Type: DRUG; Name: Placebo matched to atacicept; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): N/A
C: Arm Label: Alemtuzumab; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab; Assigned to Arm(s): Alemtuzumab | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a
D: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo / Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Teriflunomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / Teriflunomide 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo / Teriflunomide 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The purpose of this study was to establish the efficacy and safety of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous (SC) interferon beta-1a (Rebif®). The study had enrolled participants who had not previously received MS disease-modifying therapies. Participants had monthly laboratory tests and comprehensive testing every 3 months.


Options:
A: Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): N/A
B: Arm Label: ALKS 8700; Type: EXPERIMENTAL; Interventions: Drug: ALKS 8700 | Intervention Type: DRUG; Name: ALKS 8700; Assigned to Arm(s): ALKS 8700
C: Arm Label: FTY720 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: FTY720 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720 0.5 mg, FTY720 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Alemtuzumab; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab; Assigned to Arm(s): Alemtuzumab | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Oral Iron Supplementation With Sprinkles on Infectious Morbidity When Moderate to Severe Pediatric Malnutrition Is Highly Prevalent - A Non-Inferiority Safety Trial
Brief Summary: The purpose of this study is to determine the safety profile of oral iron supplementation (OIS) with Sprinkles in a pediatric population with high prevalence of Iron deficiency (ID) and moderate or severe malnutrition (MSM); the efficacy profile will also be investigated.


Options:
A: Arm Label: Multiple Intervention Arm; Type: EXPERIMENTAL; Interventions: Drug: Albendazole, Dietary Supplement: Zinc, Dietary Supplement: Multiple Micronutrient Supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Multiple Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc; Assigned to Arm(s): Multiple Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple Micronutrient Supplement; Assigned to Arm(s): Multiple Intervention Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Comprehensive; Type: EXPERIMENTAL; Interventions: Dietary Supplement: LNS-PLW, Dietary Supplement: LNS-Child | Arm Label: Child-only LNS; Type: EXPERIMENTAL; Interventions: Dietary Supplement: LNS-Child, Dietary Supplement: IFA | Arm Label: Child-only MNP; Type: EXPERIMENTAL; Interventions: Dietary Supplement: MNP, Dietary Supplement: IFA | Arm Label: Control: IFA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: IFA | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-PLW; Assigned to Arm(s): Comprehensive | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Child; Assigned to Arm(s): Child-only LNS, Comprehensive | Intervention Type: DIETARY_SUPPLEMENT; Name: MNP; Assigned to Arm(s): Child-only MNP | Intervention Type: DIETARY_SUPPLEMENT; Name: IFA; Assigned to Arm(s): Child-only LNS, Child-only MNP, Control: IFA
C: Arm Label: Micronutrient Sprinkles; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient powders (Sprinkles) | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient powders (Sprinkles); Assigned to Arm(s): Micronutrient Sprinkles
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Oral Iron Supplement | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Oral Iron Supplement; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2

Answer: D